Fig. 1: The expression of SOX17 in the normal human cervix and various cancerous cervical lesions. | Cell Death & Disease

Fig. 1: The expression of SOX17 in the normal human cervix and various cancerous cervical lesions.

From: SOX17 restrains proliferation and tumor formation by down-regulating activity of the Wnt/β-catenin signaling pathway via trans-suppressing β-catenin in cervical cancer

Fig. 1

a Immunohistochemical detection of SOX17 in normal cervix, high-grade squamous intraepithelial lesion (HSIL) and cervical cancer samples; original magnification, 1000×. b SOX17 staining is classified into three categories (negative, weak positive and strong positive), and the bar chart shows the percentage of each group (31 normal cervix specimens, 20 HSIL specimens, and 67 cervical cancer tissue specimens). c The scatter plot shows the immunoreactivity scores obtained for the staining of SOX17 in normal cervix, HSIL and invasive cervical cancer samples (points represent the IHC score per specimen, and one-way ANOVA was performed). d The expression of SOX17 in normal cervix (NC) and cervical carcinoma (CC) samples was detected using western blotting. e The relative expression of SOX17 in each normal cervix tissue (n = 8) and cervical cancer tissue sample (n = 8) is shown. The data shown are the ratios of the SOX17/GAPDH of each specimen and the means ± standard error of the NC and CC groups. *p < 0.05, *p<0.01, ***p < 0.001

Back to article page